Holen Sie sich die Stockscreener-App
51.59
2.44%
1.23
Handel nachbörslich:
51.55
-0.04
-0.08%
Schlusskurs vom Vortag:
$50.36
Offen:
$50.68
24-Stunden-Volumen:
1.45M
Relative Volume:
0.77
Marktkapitalisierung:
$4.98B
Einnahmen:
$4.10M
Nettoeinkommen (Verlust:
$-568.53M
KGV:
-8.3052
EPS:
-6.2118
Netto-Cashflow:
$-401.18M
1W Leistung:
+8.41%
1M Leistung:
+5.75%
6M Leistung:
-3.21%
1J Leistung:
+39.96%
1-Tages-Spanne:
$50.19
$51.87
1-Wochen-Bereich:
$47.20
$51.87
52-Wochen-Spanne:
$35.38
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
51.59 | 4.86B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
CRISPR Therapeutics’ SWOT analysis: gene therapy stock faces competitive pressures - Investing.com Nigeria
Needham Maintains CRISPR Therapeutics (CRSP) Buy Recommendation - MSN
Assessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline Progress - Yahoo Finance
CRISPR Therapeutics AG - TradingView
Beck Bode LLC Buys New Shares in CRISPR Therapeutics AG $CRSP - MarketBeat
Precision Trading with Crispr Therapeutics Ag (CRSP) Risk Zones - Stock Traders Daily
CRISPR Therapeutics AG (CRSP) Reports Q1 2026 Results - Insider Monkey
A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Rollout And Earnings Revisions Renew Investor Interest - Sahm
Bernstein Raises its Price Target on CRISPR Therapeutics (CRSP) - Insider Monkey
Leonteq Securities AG Makes New Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Bought by Northwestern Mutual Wealth Management Co. - MarketBeat
Crispr Therapeutics remains a Buy with strong pipeline and cash despite slow Casgevy uptake. - Pluang
CRSP Technical Analysis | Trend, Signals & Chart Patterns | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
These Are The Upcoming Catalysts For Crispr Therapeutics Stock (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics enters 'second phase' as CASGEVY momentum builds, pipeline data looms - MSN
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? - AOL.com
CRSP News | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance Singapore
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know - MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics stock (CH0334081137): gene-editing pioneer ahead of next earnings test - AD HOC NEWS
1 top Wall Street analyst thinks CRISPR Therapeutics could more than double. Should you buy the stock hand over fist? - MSN
CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Baird Maintains CRISPR Therapeutics (CRSP) Neutral Recommendation - MSN
CRISPR Therapeutics AG (HAM:1CG) Cyclically Adjusted Price-to-FCF : (As of May. 18, 2026) - GuruFocus
Is CRISPR (CRSP) Quietly Rewriting Its Gene‑Editing Priorities After Narrower Losses and Casgevy Progress? - simplywall.st
CRISPR Therapeutics AG Trade Ideas — SWB:1CG - TradingView
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms - MarketBeat
Orbis, Allan Gray report 6.3% stake in CRISPR Therapeutics (CRSP) - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI) - The Globe and Mail
CRISPR Therapeutics AG (CRSP) exceeds market returns: Some facts to consider - MSN
Capital World Investors discloses 5.1% stake in CRSP (4.93M shares) - Stock Titan
CRISPR Therapeutics stock (CH0334081137): Bernstein raises price target amid gene-editing momentum - AD HOC NEWS
CRSP Maintained by Bernstein -- Price Target Raised to $56 - GuruFocus
Vanguard Group Inc. Reduces Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Technical Reactions to CRSP Trends in Macro Strategies - Stock Traders Daily
Why Is CRISPR Therapeutics Stock in Focus Right Now - Kalkine Media
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why the market dipped but CRISPR Therapeutics AG (CRSP) gained today - MSN
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):